Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
09 11월 2023 - 9:00PM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancers, today announced that Kimberly
Blackwell, M.D., Chief Executive Officer of Zentalis, and Melissa
Epperly, MBA, Chief Financial Officer of Zentalis, will be joined
by gynecologic oncology key opinion leader, Joyce F. Liu, M.D.,
MPH, for an investor call on Friday, November 10th, at 10:00 a.m.
ET hosted by TD Cowen to discuss the azenosertib ovarian cancer
clinical updates that were announced earlier this week.
Dr. Blackwell will also participate in a fireside chat at the
Jefferies London Healthcare Conference on Wednesday, November 15th,
2023 at 8:30 a.m. GMT.
Access to live webcasts of both events, as well as archived
recordings, will be available under the “Events &
Presentations” tab on the Investors & Media section of the
Company’s website at www.zentalis.com.
About Joyce F. Liu, M.D., MPHDr. Liu received
her medical degree from Harvard Medical School in 2002. She
completed her residency in Internal Medicine at Brigham and Women's
Hospital, and her fellowship in Hematology Oncology at the
Dana-Farber Cancer Institute. In 2008, she joined the staff of
Dana-Farber and Brigham and Women's Hospital, where she is a
medical oncologist and clinical investigator in the Division of
Gynecologic Oncology. Her research focuses on identifying and
validating potential therapeutic targets in advanced
platinum-resistant ovarian cancer, in an in-vitro setting as well
as in a murine xenograft model of ovarian cancer. Dr. Liu is also
active in conducting clinical research directed towards developing
a better understanding of the basic biology of ovarian cancer and
translating discoveries from the laboratory into the clinical
setting. Dr. Liu was the presenting author on Zentalis’
GOG-3072/ZN-c3-002 study of azenosertib in combination with
chemotherapy in platinum-resistant/refractory ovarian cancer (ASCO
Annual Meeting 2023) and was also the presenting author on the
ADAGIO study of adavosertib, a legacy Wee1 inhibitor, in uterine
serous carcinoma (SGO Annual Meeting on Women’s Cancer 2023).
About Zentalis Pharmaceuticals Zentalis®
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
discovering and developing clinically differentiated small molecule
therapeutics targeting fundamental biological pathways of cancers.
The Company’s lead product candidate, azenosertib (ZN-c3), is a
potentially first-in-class and best-in-class WEE1 inhibitor for
advanced solid tumors and hematologic malignancies. Azenosertib is
being evaluated as a monotherapy and in combination across multiple
clinical trials and has broad franchise potential. In clinical
trials, azenosertib has been well tolerated and has demonstrated
anti-tumor activity as a single agent across multiple tumor types
and in combination with several chemotherapy backbones. As part of
its azenosertib clinical development program, the Company is
exploring enrichment strategies targeting tumors of high genomic
instability, such as Cyclin E1 positive tumors and homologous
recombination deficient tumors. The Company is also leveraging its
extensive experience and capabilities across cancer biology and
medicinal chemistry to advance its research on protein degraders.
Zentalis has operations in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on X/Twitter at @ZentalisP and on LinkedIn at
www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:Katie Beach Oltsik Evoke
CanaleKatherine.Beach@evokegroup.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024